- Author:
Sung Hee HAN
1
;
Jonghun LEE
Author Information
- Publication Type:Review ; English Abstract
- Keywords: Chemoprevention; Inflammatory bowel diseases; Colorectal neoplasms
- MeSH: Anti-Inflammatory Agents/therapeutic use; Chemoprevention; Colorectal Neoplasms/*complications/*prevention & control; Folic Acid/therapeutic use; Immunosuppressive Agents/therapeutic use; Inflammatory Bowel Diseases/*complications/drug therapy; Mesalamine/therapeutic use; Ursodeoxycholic Acid/therapeutic use
- From:The Korean Journal of Gastroenterology 2014;63(1):3-10
- CountryRepublic of Korea
- Language:Korean
- Abstract: The risk of developing colorectal cancer is increased in patients with inflammatory bowel disease. Surveillance colonoscopy has not been shown to prolong survival and rates of interval cancer are reported to be high. Continuing colonic inflammation has been shown to be important in the development of colorectal cancer and therefore anti-inflammatory agents such as the 5-aminosalicylates and immunomodulators have been considered as potential chemopreventive agents. This review focuses on various chemopreventive agents that have been clearly shown to reduce the risk of colorectal adenoma and cancer in the patients with inflammatory bowel disease.